NCT06712862 A Clinical Study of Evaluating Myocardial Viability in Ischemic Heart Disease with Integrated 18F-FDG PET/MR
| NCT ID | NCT06712862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai East Hospital |
| Condition | Ischemic Heart Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-31 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-12-31 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main purpose is to evaluate the accuracy of myocardial imaging obtained through integrated 18F-FDG PET/MR in detecting viable myocardium. The secondary objective is to evaluate whether myocardial imaging obtained through integrated 18F-FDG PET/MR can replace 18F-FDG PET combined with 99mTc MIBI SPECT/CT gated myocardial perfusion imaging.
Eligibility Criteria
Inclusion Criteria: 1. Adults under the age of 80 2. Coronary angiography shows coronary artery disease, with at least 2 coronary arteries having a degree of stenosis greater than 80% 3. ft ventricular ejection fraction (LVEF)\<40% 4. Acute myocardial infarction onset for at least 3 months 5. Patients with old myocardial infarction with no acute coronary artery events in the past 3 months 6. Patients of pre implementation of coronary artery bypass grafting (CABG) or combined treatment with human umbilical cord mesenchymal stem cells (iPSC) 7. Agree to participate in this clinical trial and sign an informed consent form 8. Good compliance Exclusion Criteria: * 1.Patients with diabetes or other patients with poor blood glucose control (fasting blood glucose value on the test day is greater than 10mmol/L) 2.Patients who allergy to MR contrast agent 3.Electronic implants such as pacemakers, nerve stimulators, insulin pumps, cochlear implants 4.Patients who have undergone aneurysm surgery and have intracranial aneurysm clips 5.Patients who have undergone heart surgery and have an artificial heart valve 6.Patients with metal foreign objects in the eyes 7.Patients with metal implants and prostheses, or metal foreign bodies in other parts of body 8.Severe liver and kidney dysfunction 9.Accompanied by arrhythmia such as atrial fibrillation, cerebrovascular disease, and severe pulmonary heart disease 10.Pregnant or plan to pregnant within three months or lactating women 11.Critically ill patients who require the use of life support systems 12.Patients with claustrophobia 13.Other situations which clinical trial personnel deem it inappropriate to participate in this trial
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06712862 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Ischemic Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06712862 currently recruiting?
Yes, NCT06712862 is actively recruiting participants. Contact the research team at petcenter@126.com for enrollment information.
Where is the NCT06712862 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06712862 clinical trial?
NCT06712862 is sponsored by Shanghai East Hospital. The trial plans to enroll 100 participants.